Loading...
Market
What will be the percentage reduction in Alzheimer's progression rate among patients using Lecanemab by December 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Clinical study results published in medical journals or by healthcare institutions
Story
Alzheimer's Wonder Drug Lecanemab, Biggest Breakthrough in Decades, Set for UK Approval
Aug 21, 2024, 11:46 PM
The Alzheimer's wonder drug Lecanemab is set to receive approval for use in Britain, marking a significant advancement in the treatment of the disease. This drug is the first to demonstrate the ability to slow down the progression of Alzheimer's, offering new hope to patients and healthcare providers. The approval is expected to allow Lecanemab to be prescribed privately, with potential for future availability through the National Health Service (NHS). The Medicines and Healthcare products Regulatory Agency (MHRA) is anticipated to make a favorable decision soon. While not a cure, Lecanemab represents a crucial step forward in Alzheimer's treatment, highlighting the need for increased investment in dementia services and early diagnosis. Described as the biggest breakthrough in decades, this development underscores the importance of continued research and support for Alzheimer's patients.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
More than 30% • 25%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Less than 40% • 25%
40% to 50% • 25%
50% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trials halted • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
More than 30% • 25%
Less than 20% reduction • 25%
20% to 30% reduction • 25%
31% to 40% reduction • 25%
More than 40% reduction • 25%
Less than 20% • 33%
20-40% • 33%
More than 40% • 33%